DaVita (DVA)
(Delayed Data from NYSE)
$163.08 USD
+0.82 (0.51%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $162.00 -1.08 (-0.66%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$163.08 USD
+0.82 (0.51%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $162.00 -1.08 (-0.66%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum B VGM
Zacks News
Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales
by Zacks Equity Research
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
Is Quest Diagnostics (DGX) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal Health (CAH) Streamlines Operation With New Structure
by Zacks Equity Research
Cardinal Health's (CAH) new reporting structure is likely to streamline operations, providing better visibility of growth areas. At-home solutions and OptiFreight Logistics are possibly the key value creators.
5 Mid-Cap Stocks to Buy in a Volatile January
by Nalak Das
We have narrowed our search to five mid-caps that have strong potential for 2024. These are: DVA, MNDY, GTLB, LNW, SRPT.
Here's Why Investors Should Retain Integra (IART) Stock Now
by Zacks Equity Research
Investors remain optimistic about Integra (IART) due to the positive outlook for its CSS segment.
Medtronic (MDT) Wins CE Mark for MiniMed 780G With Simplera Sync
by Zacks Equity Research
Medtronic (MDT) secures the CE Mark for the MiniMed 780G system with the disposable, all-in-one Simplera Sync CGM.
How to Find Great Momentum Stocks to Buy in 2024
by Benjamin Rains
The screen we explore today aims to find Zacks Rank #1 (Strong Buy) stocks that boast strong upward price momentum to help investors buy potential winners in January and throughout 2024.
Quest Diagnostics (DGX) to Boost Lab Services With New Buyout
by Zacks Equity Research
Quest Diagnostics' (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its strong Pharmacy model and geographical expansion.
QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind
by Zacks Equity Research
QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.
SenesTech's (SNES) New Partnership to Broaden Evolve's Scope
by Zacks Equity Research
The collaboration with a global leader in irrigation solutions for sustainable agriculture aligns with SenesTech's (SNES) target to introduce Evolve to a broader audience.
PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales
by Zacks Equity Research
PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.
Inspire Medical (INSP) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inspire Medical's (INSP) revenue growth in the fourth quarter is likely to have been boosted by improved operating leverage.
DexCom (DXCM) Preliminary Q4 Revenues Ride on Sensor Demand
by Zacks Equity Research
DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.
Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio
by Zacks Equity Research
Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision's (EYE) stock, banking on strong solvency and promising future strategies.
Tandem Diabetes (TNDM) and Abbott Debut New Integrated Offering
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 is the first AID system to be integrated with Abbott's Freestyle Libre 2 Plus sensor.
Best Growth Stocks to Buy for January 9th
by Zacks Equity Research
EG, BROS and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 9, 2024.
Illumina (ILMN) Extends Partnership to Advance Cancer Test
by Zacks Equity Research
Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) led by solid prospects in the Diagnostic business and raised guidance.
Chemed (CHE) Roto-Rooter Growth Continues, Macro Issues Hurt
by Zacks Equity Research
Within the Hospice segment, Chemed (CHE) is well poised to register growth driven by the growing aging population.
Asensus Surgical (ASXC) Completes Surgeon Lab for LUNA
by Zacks Equity Research
Asensus Surgical's (ASXC) latest Surgeon Lab helps it move closer to a finalized LUNA product.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
AngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in second-quarter fiscal 2024.
Boston Scientific (BSX) Rides on Global Growth Amid Macro Woes
by Zacks Equity Research
Within APAC, Boston Scientific (BSX) is registering strong growth in Japan and China.